- Report
- February 2026
- 250 Pages
Global
From €4139EUR$4,490USD£3,456GBP
- Report
- November 2026
- 179 Pages
Global
From €5393EUR$5,850USD£4,503GBP
- Report
- February 2026
- 250 Pages
Global
From €4139EUR$4,490USD£3,456GBP
- Report
- February 2026
- 250 Pages
Global
From €4139EUR$4,490USD£3,456GBP
- Drug Pipelines
- September 2026
- 150 Pages
Global
From €3457EUR$3,750USD£2,886GBP
- Report
- August 2026
- 106 Pages
Global
From €4379EUR$4,750USD£3,656GBP
- Report
- July 2026
- 160 Pages
Global
From €4379EUR$4,750USD£3,656GBP
- Report
- April 2026
- 180 Pages
Global
From €4379EUR$4,750USD£3,656GBP
- Report
- August 2026
- 160 Pages
Global
From €3061EUR$3,320USD£2,555GBP
€3826EUR$4,150USD£3,194GBP
- Report
- July 2026
- 160 Pages
Global
From €3061EUR$3,320USD£2,555GBP
€3826EUR$4,150USD£3,194GBP
- Report
- August 2020
- 250 Pages
Saudi Arabia
From €3319EUR$3,600USD£2,771GBP
- Report
- August 2026
- 120 Pages
Mexico
From €4379EUR$4,750USD£3,656GBP
- Report
- February 2024
- 85 Pages
North America
From €4379EUR$4,750USD£3,656GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4379EUR$4,750USD£3,656GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4379EUR$4,750USD£3,656GBP
- Report
- February 2024
- 90 Pages
Asia Pacific
From €4379EUR$4,750USD£3,656GBP
- Report
- February 2024
- 80 Pages
Latin America
From €4379EUR$4,750USD£3,656GBP
- Report
- February 2024
- 90 Pages
South Korea
From €4379EUR$4,750USD£3,656GBP
- Report
- February 2024
- 70 Pages
Philippines
From €4379EUR$4,750USD£3,656GBP
- Report
- February 2024
- 70 Pages
India
From €4379EUR$4,750USD£3,656GBP

Toujeo is a long-acting insulin used to treat adults with type 1 and type 2 diabetes. It is a part of the Endocrine and Metabolic Disorders Drugs market, which includes medications used to treat a variety of conditions, such as diabetes, thyroid disorders, and obesity. Toujeo is a once-daily, long-acting insulin that helps to control blood sugar levels. It is designed to provide a steady, consistent level of insulin throughout the day, helping to reduce the risk of hypoglycemia.
The Endocrine and Metabolic Disorders Drugs market is a rapidly growing sector, with a wide range of products available to treat a variety of conditions. Companies in this market include Sanofi, Novo Nordisk, Eli Lilly, Merck, and AstraZeneca. Show Less Read more